Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906398 | 0.89 | RAB9A (0.62) | RAB9ANPC1HDAC3NCOR2KMT2A | |
| SCHEMBL15265396 | 0.84 | NPC1 (0.57) | RAB9ANPC1HDAC3NCOR2 | |
| SCHEMBL7275144 | 0.81 | NPC1 (0.57) | RAB9ANPC1HDAC3NCOR2ALDH1A1 | |
| SCHEMBL19328790 | 0.80 | ALDH1A1 (0.59) | RAB9ANPC1ALDH1A1 | |
| SCHEMBL18500725 | 0.78 | SYK (0.51) | RAB9ANPC1KMT2A | |
| SCHEMBL13296294 | 0.78 | KMT2A (0.56) | RAB9AKMT2AGAAALDH1A1 | |
| SCHEMBL13087734 | 0.78 | NPC1 (0.57) | RAB9ANPC1HDAC3NCOR2ALDH1A1 | |
| SCHEMBL2037095 | 0.78 | NPC1 (0.57) | RAB9ANPC1HDAC3NCOR2KMT2A | |
| SCHEMBL27562115 | 0.76 | RAB9A (0.47) | RAB9ANPC1HDAC3NCOR2KMT2A | |
| SCHEMBL13314114 | 0.76 | NPC1 (0.59) | RAB9ANPC1HDAC3NCOR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070048752-A1 | Mass tags for quantitative analyses | APPLERA CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070048752-A1 | Mass tags for quantitative analyses | SRMS, PTMS, TMT1A | RAB9A 3550/4885NPC1 2758/4885HDAC3 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.